Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight

Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight

Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life...

Full description

Bibliographic Details
Main Authors: Claudia Ielo, Francesca Fazio, Serena Rocchi, Ilaria Rizzello, Katia Mancuso, Elena Zamagni, Michele Cavo, Maria Teresa Petrucci
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Leukemia Research Reports
Subjects:
Multiple myeloma
Cellular therapies
Infectious complications
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048923000390

Internet

http://www.sciencedirect.com/science/article/pii/S2213048923000390

Similar Items